Researchers at Sahlgrenska Academy, in Gothenburg, Sweden, have finalized the clinical pharmacokinetic trial where Infudopa SubC™ and Infudopa IntraV™ have been compared with Duodopa®/Duopa® with respect to serum levodopa levels in 18 patients with late stage Parkinson´s disease. Dizlin Pharmaceuticals expect analyzed data in H2 2020.
Henrik Martinsson has been appointed CCO of Dizlin Pharmaceuticals and he joined the company on October 1st.
Henrik Martinsson has worked 20 years in the medical device business, mostly for Abbott in different roles. Most recently, he was the CEO for a Swedish distributor company selling medical device equipment within Ophthalmology to hospitals, private clinics and opticians.
“We are happy to bring Henrik Martinsson onboard our team. He will bring an extensive additional knowledge to Dizlin Pharmaceuticals with respect to business development and in the area of medical devices,” says Björn Velin, CEO of Dizlin Pharmaceuticals AB.
In order to further strengthen Dizlin Pharmaceuticals’ collaboration with researchers at the Sahlgrenska Academy at the University of Gothenburg, the company has agreed to sponsor a PhD position at the Department of Pharmacology.
The research collaboration is focused on Parkinson’s disease with the aim to get new insights in the understanding of the brain disorder. This can be of great value for Dizlin Pharmaceuticals in the company’s ambition to develop innovative and effective products that improve the quality of life for Parkinson patients.
The headquarters of Dizlin Pharmaceuticals was relocated to Gothenburg as of September 1st.
“The relocation of our headquarters to Gothenburg enables us to be closer to the Sahlgrenska Academy and the Sahlgrenska University Hospital in Gothenburg where most of our research is being undertaken,“ says Björn Velin, CEO of Dizlin Pharmaceuticals AB.
The company’s headquarters was previously located in Uppsala
Dizlin Pharmaceuticals has appointed Björn Velin as CEO and he joined the company as of September 1st. Björn Velin has a long and solid experience from the pharmaceutical industry and especially from leading positions in the areas of sales and development of medical drugs for treatment of diseases in the central nervous system.
Björn Velin has worked for more than 25 years at Lundbeck in various roles and most recently as President of Lundbeck in Japan.
“We are pleased to announce the recruitment of Björn Velin as CEO of Dizlin Pharmaceuticals. This appointment marks an important step for the development of our business and the future of the company,” comments Leif Bring, Chairman of the Board.